OPKO Health, Inc.
corporate_fare Company Profile
OPKO Health, Inc. (NASDAQ:OPK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for OPK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for OPK spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- OPKO 10-Q Details Q3 Loss, $403M Cash and BioReference Held-for-Sale Ahead of $722M Labcorp Deal
- OPKO Q3 Revenue Up 16% to $65.4M; Services Guidance Withdrawn Ahead of Labcorp Deal
- OPKO Q3 Revenue Up 16% as BioReference Sale Reshapes Reporting
- OPKO to Sell BioReference Lab Testing Business to Labcorp for $722M Cash
- OPKO's $121M Convertible Notes Become Convertible Through Year-End
Financial Snapshot
Short Interest & Short Volume
9.23 days to coverFINRA reported short interest of 32,849,261 shares in OPK as of the October 30, 2026 settlement, a 3.4% decrease from the prior period — about 9.2 days to cover at its recent average daily volume. On November 20, 2026, 42.2% of OPK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for OPK, detected from its recent SEC filings · based on capital-structure filings through 2026-10-02.
Convertible Notes Triggered · Share Settlement Elected
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →